Abstract：
Drug repurposing has emerged as an attractive strategy for accelerating drug discovery for cancer treatment. In this study, we investigated combining Tranylcypromine (TCP) with a number of well-characterized drugs. Among these combinations, NRF2 inhibitor (ML385) exhibited synergistic effects in combination with TCP. Specifically, our results showed that the combination of TCP and ML385 resulted in a significant reduction in tumor proliferation while neither drug affected cancer cell growth meaningfully on its own. While further studies are needed to understand fully the extent of the synergistic efficacy, the underlying respective mechanisms and the potential side effects of this approach, our study has yielded a promising start for the development of an effective combination cancer therapy.
摘要：
药物再利用已经成为加速癌症治疗药物发现的有吸引力的策略。在这项研究中,我们研究了转酰环丙胺（TCP）与许多特征明确的药物的组合。在这些组合中，ML385与TCP组合显示出协同作用。具体来说,我们的结果显示,TCP和ML385的组合导致肿瘤增殖显著减少,而两种药物本身均未显著影响癌细胞生长.虽然需要进一步的研究来充分了解协同功效的程度，这种方法的潜在机制和潜在副作用，我们的研究为开发有效的联合癌症疗法提供了一个有希望的开端.
